Literature DB >> 9879994

ETS2 function is required to maintain the transformed state of human prostate cancer cells.

V I Sementchenko1, C W Schweinfest, T S Papas, D K Watson.   

Abstract

The contribution of the ETS2 transcription factor to the transformed state in prostate cancer cells has been assessed. Northern blot analysis easily detects ETS2 in DU145 and PC3, high grade human prostate cell lines, but ETS2 is not present in lower grade LNCaP cells. Stable transfection of PC3 and DU145 prostate cell lines with an antisense ETS2 vector or with a dominant negative ETS2 mutant significantly reduced the ability of DU145 and PC3 cells to form large colonies in soft agar. Thus, the presence of ETS2 is positively correlated with a more transformed phenotype and blockage of ETS2 function can reduce transformed properties of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9879994     DOI: 10.1038/sj.onc.1202220

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Overexpression of ETS2 in human esophageal squamous cell carcinoma.

Authors:  Xin Li; Jia-Yun Lu; Li-Qun Zhao; Xiu-Qin Wang; Gui-Lin Liu; Zhong Liu; Chuan-Nong Zhou; Min Wu; Zhi-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

2.  The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells.

Authors:  Peter C Hollenhorst; Litty Paul; Mary W Ferris; Barbara J Graves
Journal:  Genes Cancer       Date:  2011-01-01

3.  ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer.

Authors:  Ignacio I Wistuba; Humam Kadara; Mohamed Kabbout; Melinda M Garcia; Junya Fujimoto; Diane D Liu; Denise Woods; Chi-Wan Chow; Gabriela Mendoza; Amin A Momin; Brian P James; Luisa Solis; Carmen Behrens; J Jack Lee
Journal:  Clin Cancer Res       Date:  2013-05-09       Impact factor: 12.531

4.  Highly specific role of the insulin receptor in breast cancer progression.

Authors:  Ran Rostoker; Sagi Abelson; Keren Bitton-Worms; Inna Genkin; Sarit Ben-Shmuel; Maria Dakwar; Zila Shen Orr; Avishay Caspi; Maty Tzukerman; Derek LeRoith
Journal:  Endocr Relat Cancer       Date:  2015-04       Impact factor: 5.678

5.  Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.

Authors:  Giuseppina M Carbone; Sara Napoli; Alessandra Valentini; Franco Cavalli; Dennis K Watson; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2004-08-16       Impact factor: 16.971

6.  Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.

Authors:  Dakang Xu; Julie Dwyer; He Li; Wei Duan; Jun-Ping Liu
Journal:  J Biol Chem       Date:  2008-06-27       Impact factor: 5.157

7.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

8.  Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Authors:  William C Krause; Ayesha A Shafi; Manjula Nakka; Nancy L Weigel
Journal:  Int J Biochem Cell Biol       Date:  2014-07-04       Impact factor: 5.085

9.  Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.

Authors:  Giuseppina M Carbone; Eileen M McGuffie; Angela Collier; Carlo V Catapano
Journal:  Nucleic Acids Res       Date:  2003-02-01       Impact factor: 16.971

10.  ERG is specifically associated with ETS-2 and ETV-4, but not with ETS-1, in prostate cancer.

Authors:  David Adler; Jacqueline Ochsenfahrt; Kerstin Fuchs; Glen Kristiansen; Sven Perner; Nicolas Wernert
Journal:  Int J Mol Med       Date:  2012-08-20       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.